BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19958855)

  • 1. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
    Camenzind E; Wijns W; Mauri L; Boersma E; Parikh K; Kurowski V; Gao R; Bode C; Greenwood JP; Gershlick A; O'Neill W; Serruys PW; Jorissen B; Steg PG;
    Am Heart J; 2009 Dec; 158(6):902-909.e5. PubMed ID: 19958855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
    Wijns W; Steg PG; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Lipsic E; Alamgir F; Rademaker-Havinga T; Boersma E; Radke P; van Leeuwen F; Camenzind E;
    Eur Heart J; 2014 Oct; 35(40):2812-20. PubMed ID: 25106761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry).
    Planer D; Beyar R; Almagor Y; Banai S; Guetta V; Miller H; Kornowski R; Brandes S; Krakover R; Solomon M; Lotan C
    Am J Cardiol; 2008 Apr; 101(7):953-9. PubMed ID: 18359314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Suttorp MJ; Laarman GJ;
    Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
    Serruys PW; Silber S; Garg S; van Geuns RJ; Richardt G; Buszman PE; Kelbaek H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Ronden J; Bressers M; Gobbens P; Negoita M; van Leeuwen F; Windecker S
    N Engl J Med; 2010 Jul; 363(2):136-46. PubMed ID: 20554978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
    Kim BK; Oh S; Jeon DW; Yang JY; Kim JS; Park S; Choi D; Jang Y; Hong BK; Kwon HM; Lee SW; Goh CW; Kwon K; Ryu SK;
    J Interv Cardiol; 2009 Oct; 22(5):411-9. PubMed ID: 19702679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
    Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
    Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
    Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE;
    Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.
    Valgimigli M; Patialiakas A; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C
    Am Heart J; 2013 Nov; 166(5):831-8. PubMed ID: 24176438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study).
    Rahel BM; Laarman GJ; Kelder JC; Ten Berg JM; Suttorp MJ
    Am Heart J; 2009 Jan; 157(1):149-55. PubMed ID: 19081412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.
    Pfisterer M; Bertel O; Bonetti PO; Brunner-La Rocca HP; Eberli FR; Erne P; Galatius S; Hornig B; Kiowski W; Pachinger O; Pedrazzini G; Rickli H; De Servi S; Kaiser C;
    Am Heart J; 2008 Apr; 155(4):609-14. PubMed ID: 18371466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.